Literature DB >> 8024357

Recurrent squamous cell carcinoma of the anal canal. Predictors of initial treatment failure and results of salvage therapy.

W E Longo1, A M Vernava, T P Wade, M A Coplin, K S Virgo, F E Johnson.   

Abstract

OBJECTIVE: The outcomes of patients with squamous cell carcinoma of the anal canal treated by either sphincter-preserving procedures or radical surgery were evaluated, with the goals of identifying factors predicting treatment failure and quantifying results of salvage therapy in patients with recurrent disease. BASIC PROCEDURES: A population-based study on all patients in all 159 hospitals of the Department of Veterans Affairs (VA) from 1987 to 1991 was carried out. Data were compiled from several national computerized VA data sets. Supplementary information from local tumor registrars also was obtained, including demographic information, discharge summaries, operative reports, pathology reports, and medical oncology and radiation oncology summaries. From these sources, information on tumor histology, tumor stage, tumor grade, presence of regional or distant metastases, surgical procedures, use of chemotherapy and radiation therapy (RT), toxicity of chemotherapy and RT, development of recurrent disease, treatment of recurrence, survival, and cause of death were obtained. MAIN
FINDINGS: Four hundred five patients with anal cancer were identified by computer search, and 204 (51%) were evaluable; 164 of 204 (80%) had squamous cell carcinoma, 137 of whom (84%) were treated with sphincter-preserving procedures, and 27 of whom (16%) were treated by by radical surgery. One hundred fourteen of 138 (83%) were treated by multimodality therapy, which we defined as local excision followed by chemotherapy and RT. The mean dose of RT among patients treated by multimodality therapy was 4200 +/- 540 cGy and 82% of those treated with multimodality therapy received 5-FU/mitomycin C. Recurrent disease was diagnosed in 43 of all 149 patients (29%) with potentially curable disease. (stages I-III) Multivariate analysis revealed that stage at diagnosis (p = 0.04) and method of treatment (p = 0.03) were the sole predictors of recurrence. Fifty-three percent of patients who underwent salvage abdominoperineal resection (APR) are alive, whereas only 19% who underwent salvage chemotherapy with or without RT are alive. PRINCIPAL
CONCLUSIONS: These data indicate that multimodality therapy currently is being employed in the majority of patients with squamous cell carcinoma of the anal canal in the VA system. Tumor stage and method of treatment appear to affect the likelihood of development of recurrent disease. Salvage APR has curative potential. Results with salvage chemotherapy and RT are disappointing.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8024357      PMCID: PMC1234285          DOI: 10.1097/00000658-199407000-00007

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  41 in total

1.  Cancer of the anal canal: report on the experience of 61 patients.

Authors:  J B Dubois; J M Garrigues; H Pujol
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-03       Impact factor: 7.038

Review 2.  Anal and para-anal tumors.

Authors:  S H Quan
Journal:  Surg Clin North Am       Date:  1978-06       Impact factor: 2.741

3.  Radiation therapy in the management of epidermoid carcinoma of the anal region.

Authors:  J Papillon
Journal:  Dis Colon Rectum       Date:  1974 Mar-Apr       Impact factor: 4.585

4.  Cancer of the anal canal.

Authors:  M W Stearns; C Urmacher; S S Sternberg; J Woodruff; F Attiyeh
Journal:  Curr Probl Cancer       Date:  1980-06       Impact factor: 3.187

5.  Primary radiation therapy in the treatment of anal canal carcinoma.

Authors:  B J Cummings; G M Thomas; T J Keane; A R Harwood; W D Rider
Journal:  Dis Colon Rectum       Date:  1982 Nov-Dec       Impact factor: 4.585

6.  Epidermoid carcinoma of the anus.

Authors:  J Boey; J Wong; G B Ong
Journal:  Aust N Z J Surg       Date:  1982-10

7.  Current management of carcinoma of the anus and perianus.

Authors:  J L Sawyers
Journal:  Am Surg       Date:  1977-07       Impact factor: 0.688

8.  Carcinoma of the anus.

Authors:  O H Beahrs; S M Wilson
Journal:  Ann Surg       Date:  1976-10       Impact factor: 12.969

9.  Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal.

Authors:  N D Nigro; H G Seydel; B Considine; V K Vaitkevicius; L Leichman; J J Kinzie
Journal:  Cancer       Date:  1983-05-15       Impact factor: 6.860

10.  Combined therapy for cancer of the anal canal.

Authors:  N D Nigro; V K Vaitkevicius; T Buroker; G T Bradley; B Considine
Journal:  Dis Colon Rectum       Date:  1981 Mar-Apr       Impact factor: 4.585

View more
  13 in total

Review 1.  Current understanding and potential immunotherapy for HIV-associated squamous cell carcinoma of the anus (SCCA).

Authors:  Christian Marin-Muller; Min Li; Changyi Chen; Qizhi Yao
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

2.  [Curative radiotherapy in patients with anal cancer: clinical outcomes and prognostic factors in a single-institution experience].

Authors:  M F Osti; L Agolli; C Scaringi; S Bracci; G Minniti; R Maurizi Enrici
Journal:  Radiol Med       Date:  2012-11-26       Impact factor: 3.469

3.  Epidermoid cancer of the anal canal.

Authors:  Shawn P Webb; Chong S Lee
Journal:  Clin Colon Rectal Surg       Date:  2011-09

4.  The treatment of squamous anal carcinoma: guidelines of the Italian Society of Colo-Rectal Surgery.

Authors:  I Giani; M Mistrangelo; C Fucini
Journal:  Tech Coloproctol       Date:  2012-11-10       Impact factor: 3.781

5.  Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy.

Authors:  B C van der Wal; B I Cleffken; B Gulec; H S Kaufman; M A Choti
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

6.  Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11).

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

7.  Surgical salvage therapy of anal cancer.

Authors:  Yue-Kui Bai; Wen-Lan Cao; Ji-Dong Gao; Jun Liang; Yong-Fu Shao
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

8.  [Diagnosis and therapy for anal carcinoma].

Authors:  W Heitland
Journal:  Chirurg       Date:  2008-02       Impact factor: 0.955

9.  Postoperative versus definitive chemoradiation in early-stage anal cancer. Results of a matched-pair analysis.

Authors:  B Berger; M Menzel; G Breucha; M Bamberg; M Weinmann
Journal:  Strahlenther Onkol       Date:  2012-05-10       Impact factor: 3.621

10.  Prognostic factors for squamous cell cancer of the anal canal.

Authors:  Prajnan Das; Christopher H Crane; Cathy Eng; Jaffer A Ajani
Journal:  Gastrointest Cancer Res       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.